Drug Trial Radar · NCT07568236
A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)
Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Oct 5, 2026
Primary completion
Dec 31, 2027
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Chinese University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical study to investigates the efficacy of fezolinetant in men undergoing ADT for prostate cancer in alleviating Vasomotor syndromes.
Conditions
- Vasomotor Symptoms
- Prostate Cancer
Interventions
FezolinetantDrug
Fezolinetant 45 mg orally once daily for 12 weeks.
PlaceboDrug
Placebo orally once daily for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hot flush severityTime frame: Baseline, week 3, week 7 and week 11
- Daily hot flush scoreTime frame: Baseline, week 3, week 7 and week 11
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Prince of Wales Hospital
Shatin, Hong Kong · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.